Pelthos (PTHS) Q1 2026 earnings review
Strong Volume Overshadowed by Deteriorating Unit Economics
Pelthos reported a top-line beat with Q1 net product revenue growing 17% sequentially to $10.7M, driven by a 25% surge in ZELSUVMI dispensed units. However, execution on volume masks a concerning financial reality: the path to profitability is getting steeper. Net revenue per unit declined ~6% QoQ as Gross-to-Net (GTN) pressures materialized. Despite a $1.6M increase in gross profit, a 14% spike in SG&A drove the operating loss wider to $13.1M. While the headline Net Loss appears dramatically better (-$10.2M vs -$21.7M in 25Q4), this was entirely manufactured by a non-cash $5.2M gain on debt valuation. The core business is burning more cash, not less.
🐂 Bull Case
ZELSUVMI volume is Accelerating. The company dispensed 7,884 units in Q1 (+25% QoQ) and reported 3,776 units dispensed in April alone, implying a Q2 run-rate well over 11,000 units.
The planned expansion to 64 territory managers is complete. This larger footprint directly targets high-volume metropolitan areas and is already translating to rapid prescriber acquisition (3,228 unique prescribers in Q1).
🐻 Bear Case
Unit volume grew 25%, but revenue only grew 17%. Implied net revenue per unit dropped from ~$1,440 in Q4 to ~$1,352 in Q1, validating previous management warnings about higher PBM and Medicaid rebates compressing margins.
Expenses are outrunning growth. SG&A jumped by $2.6M QoQ, while Gross Profit only increased by $1.6M. Achieving the previously stated goal of 'cash flow positivity by end of 2026' looks increasingly difficult without aggressive cost containment.
⚖️ Verdict: ⚪
Neutral. The commercial rollout of ZELSUVMI as a first-in-class at-home therapy is a textbook success. However, the widening operating loss and falling net unit price mean investors are paying for expensive revenue growth that isn't dropping to the bottom line.
Key Themes
ZELSUVMI Adoption is Accelerating
The first at-home FDA-approved treatment for molluscum contagiosum is gaining serious traction. Q1 saw 7,884 units dispensed, up 25% sequentially. More importantly, April saw 3,776 units dispensed. If April's pace holds, Q2 will see >11,000 units dispensed, representing a potential 40%+ sequential growth rate. This confirms that digital awareness campaigns and prescriber targeting are successfully disrupting the traditional 'wait and see' pediatric approach.
Net Unit Economics are Decelerating
A specific contradiction to the positive revenue narrative: while total sales are up, the quality of each sale is down. Dividing net product revenue by units dispensed reveals implied net revenue per unit fell from ~$1,440 in Q4 to ~$1,352 in Q1. This ~6% compression reflects the 'Gross-to-Net (GTN) normalization' management warned about previously, driven by a new PBM contract and high Medicaid utilization. Volume must run faster just to maintain revenue growth.
Sales Force Expansion Complete
The company successfully expanded its sales force from 50 to 64 territory managers. This 28% increase in headcount allows Pelthos to cover previously untargeted major metropolitan areas. This is the primary driver behind the jump to 3,228 unique prescribers in Q1.
Operating Losses are Reversing their Improvement
In Q4, operating loss improved from $15.4M to $12.0M. In Q1, that trend Reversing, with operating loss widening to $13.1M. SG&A surged 14% QoQ to $21.1M. While management notes $1.6M in corporate expense reductions, these were completely overwhelmed by a $1.5M increase in sales/marketing, $1.2M in regulatory/manufacturing, and $1.0M in personnel costs. The company is not yet achieving economies of scale.
Debt and Interest Burden Accumulating
The balance sheet requires monitoring. Pelthos drew $30M from a new Horizon term loan at steep terms (Prime + 3.75%). Consequently, quarterly interest expense nearly doubled QoQ, jumping from $1.3M to $2.4M. With $32M in cash and a quarterly Adjusted EBITDA burn of $8.0M, the runway is sufficient for now, but debt servicing will consume an increasing share of gross profits.
Favorable Seasonality Approaching
Historically, the molluscum contagiosum market experiences peak patient visits during the warmer months (March through October). As Pelthos enters Q2 and Q3 with a fully staffed sales force and broad PBM coverage, the company is positioned to capitalize on this natural seasonal tailwind, which should further support volume acceleration.
Other KPIs
Decelerating. The non-GAAP loss widened from $(7.6) million in Q4 2025. Despite stripping out stock-based compensation, depreciation, and the massive $5.2M non-cash gain on debt, the core cash-burn metric worsened due to the expanded sales force and marketing costs.
Stable. COGS remained flat at $1.7M sequentially despite a 25% increase in dispensed units. This indicates excellent manufacturing leverage and improving gross margins (84% in Q1 vs 81% in Q4), though COGS is still temporarily inflated by fair-value inventory step-ups from the 2025 merger.
This non-cash paper gain on the November 2025 convertible notes single-handedly reduced the GAAP Net Loss. In Q4, this same line item was a $15.0M paper loss. Investors should strip this out entirely to understand true operational performance.
Guidance
Accelerating. This single-month figure represents 48% of the entire Q1 volume. If annualized across Q2, it implies ~11,300 units, indicating a massive sequential growth step-up as seasonality and new sales reps take effect.
Stable. The company reiterated its launch timeline for its two acquired assets. These will leverage the existing 64-person dermatology/pediatric sales force, though launch preparation costs (estimated in prior calls at low single-digit millions) will weigh on SG&A throughout late 2026.
Key Questions
Gross-to-Net (GTN) Floor
Implied net revenue per unit fell ~6% this quarter as the new PBM contract took effect. Where do you expect GTN to stabilize as a percentage of WAC, and have we hit the floor for net unit pricing?
SG&A Trajectory
With the 14-rep expansion now complete, should we view Q1's $21.1M SG&A as a stabilized plateau for the remainder of 2026, or will marketing and pre-launch costs for XEPI drive this higher?
Path to Breakeven
In prior quarters, management guided to cash flow positivity by the end of 2026. Given the widening operating loss in Q1 and increased interest burden from the Horizon facility, are you reiterating that timeline?